Ripston
↗New York, USA
Ripston is a boutique strategic communications and investor relations firm dedicated exclusively to the life sciences, biotechnology, and healthcare sectors. The firm specializes in helping emerging and established biotech companies articulate their scientific value propositions to investors, media, and the broader medical community.
As a specialized service provider, Ripston operates at the intersection of science and finance, offering services such as corporate branding, IPO preparation, clinical data communications, and executive thought leadership. The firm is known for its deep industry relationships and its ability to navigate the complex regulatory and scientific landscape of the pharmaceutical industry.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Strategic Communications
Sub-Industry:Life Sciences Public Relations & Investor Relations
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$5M
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Self-funded / Bootstrapped
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Collaborates with various venture capital firms and investment banks to support portfolio companies.
COMPETITION
Position:Niche Player
Competitors:Argot Partners, Stern Investor Relations, Real Chemistry, LaVoieHealthScience, Solebury Strategic Communications
LEADERSHIP
Key Executives:
Sabrina Ripston - Founder & Managing Director
LINKS
Website:ripston.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ripston. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.